- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01707030
Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
As many as 80% of Veterans with the hepatitis C virus (HCV) engage in harmful drinking. This is a major health challenge given that even light and moderate alcohol consumption can worsen the course and consequences of HCV and can be a barrier to receiving antiviral therapy. In response, the VA Uniform Mental Health Services Package has made it a priority that HCV and other ambulatory clinics provide evidence-based mental health services to all Veterans engaging in harmful drinking within two week (but preferably the same day as the clinic visit). The investigators' CREATE partners, the VA Office of Mental Health Services, VA Operations (10N), and the VA Office of Public Health, are strongly committed to achieving this standard throughout the Veterans Health Administration (VHA). However, the cost and organizational challenges to meeting this mandate in HCV clinics are enormous, but may be surmountable through the use of self-directed technology that minimizes demands on scarce staff time.
The primary objective of this study is to implement and evaluate a web-based brief alcohol intervention (BAI) for treating Veterans with HCV and seeking care at two VA HCV clinics - Veterans Affairs Palo Alto Health Care System (VAPAHCS) and San Francisco Veterans Affairs Medical Center (SFVAMC). This study will have three aims: First (Aim 1), the investigators plan to assess patient, provider, and system factors that may impact the initial adoption of this intervention in two VA HCV clinics. These data will result in the development of a protocol for the initial implementation of the web-based BAI at the investigators' two study sites. A secondary aim will involve obtaining patient and provider feedback on an existing web-based BAI (see www.bmi-aft.org, VA Intranet Only) to help inform its redesign for use with this population. Second (Aim 2), the investigators will implement and examine the effectiveness of a web-based BAI in two HCV clinics to reduce alcohol consumption in Veterans with HCV at three- and six-months post-treatment. Third (Aim 3), the investigators will conduct a budget impact analysis to estimate the short-term costs (1-3 years) of adoption and diffusion of the web-based BAI and the trajectory of health care spending for study participants.
This mixed-methods study will utilize qualitative and quantitative methods to achieve its three primary aims. To address aim 1, qualitative interviews will be used to collect data that will inform the initial implementation and re-versioning of a web-based BAI for use in two HCV clinics located at the Palo Alto and San Francisco. To address aim 2, the investigators will use a randomized, hybrid (type 1) design with patient level clinical outcome data and formative evaluation data collected to examine the effectiveness of the web-based BAI. "Hybrid" designs also integrate formative evaluation into experimental designs to identify factors that impact the effectiveness of implementation efforts. Formative evaluation (e.g., site visits, clinic observation, and interviews with staff and patients) will be used to improve the adoption of the web-based BAI at both sites and to provide evidence-based guidance to the investigators' CREATE operational partners for nationwide implementation. To address aim 3, the investigators will conduct a budget impact analysis to estimate the short-term costs (1-3 years) of adoption and diffusion of the web-based BAI and the trajectory of health care spending for study participants. The investigators plan to collect several types of utilization data, including outpatient, inpatient, and pharmacy utilization, and calculate total dollars.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Palo Alto, California, États-Unis, 94304-1290
- VA Palo Alto Health Care System, Palo Alto, CA
-
San Francisco, California, États-Unis, 94121
- San Francisco VA Medical Center, San Francisco, CA
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Must be a US military veteran.
- Over the age of 17 with liver disease.
- Must be receiving care at a VA liver clinic.
Exclusion Criteria:
- Those with no current or historical use of alcohol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: BAI Arm
Receiving a web-based brief intervention for alcohol problems
|
Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
All patients will be receiving care in a Hepatitis C clinic.
In some cases clinicians may counsel them on alcohol problems.
|
Comparateur actif: Usual Care
In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
|
All patients will be receiving care in a Hepatitis C clinic.
In some cases clinicians may counsel them on alcohol problems.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in Days of Unhealthy Alcohol Consumption
Délai: Baseline, 3 months, and 6 months
|
The number of days on which alcohol was consumed beyond recommended levels in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Change in Drinking Days
Délai: Baseline, 3 months, and 6 months
|
The number of days on which alcohol was consumed at any level in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in Drinks Per Drinking Day
Délai: Baseline, 3 months, and 6 months
|
The number of standard drinks (0.5 ounce ethanol equivalent) consumed on those days that an individual drank in the last 30 days.
|
Baseline, 3 months, and 6 months
|
Change in Symptoms of Psychological Distress (PHQ-9)
Délai: Baseline, 3 months, and 6 months
|
Symptoms of psychological distress will be measured using the Patient Health Questionnaire (PHQ-9).
The PHQ-9 provides an assessment of depression severity.
The minimum value is 0 and the maximum value is 27.
Lower scores are better.
The reliability, validity, and clinical utility of the PHQ-9 instrument are well-established.
|
Baseline, 3 months, and 6 months
|
Change in SF-12 Physical Health Composite
Délai: Baseline, 3 months, and 6 months
|
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population .
The SF-12 has demonstrated good internal consistency reliability and construct validity.
This reflects the physical health component of the SF-12.
Scores range from 0-100 and higher scores are better.
|
Baseline, 3 months, and 6 months
|
Change in Additional Care
Délai: Baseline and 12 months
|
Total costs in dollars of all VA and non-VA inpatient, outpatient and pharmacy costs.
|
Baseline and 12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in SF-12 Mental Health Composite
Délai: Baseline, 3 months, and 6 months
|
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population.
The SF-12 has demonstrated good internal consistency reliability and construct validity.
This reflects the mental health component of the SF-12.
Scores range from 0-100 and higher scores are better.
|
Baseline, 3 months, and 6 months
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22-35. doi: 10.1080/10550887.2016.1100960. Epub 2015 Oct 14.
- Cucciare MA, Timko C. Bridging the gap between medical settings and specialty addiction treatment. Addiction. 2015 Sep;110(9):1417-9. doi: 10.1111/add.12977. No abstract available.
- Cucciare MA, Cheung RC, Rongey C. Treating substance use disorders in patients with hepatitis C. Addiction. 2015 Jul;110(7):1057-9. doi: 10.1111/add.12893. Epub 2015 Mar 27. No abstract available.
- Timko C, Kong C, Vittorio L, Cucciare MA. Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review. J Clin Nurs. 2016 Nov;25(21-22):3131-3143. doi: 10.1111/jocn.13244. Epub 2016 May 3.
- Cucciare MA, Jamison AL, Combs AS, Joshi G, Cheung RC, Rongey C, Huggins J, Humphreys K. Adapting a computer-delivered brief alcohol intervention for veterans with Hepatitis C. Inform Health Soc Care. 2017 Dec;42(4):378-392. doi: 10.1080/17538157.2016.1255628. Epub 2017 Jan 9.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Les troubles mentaux
- Troubles induits chimiquement
- Maladies du système digestif
- Troubles liés à l'alcool
- Troubles liés à une substance
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections transmissibles par le sang
- Maladies transmissibles
- Maladies du foie
- Infections à Flaviviridae
- Hépatite, virale, humaine
- Infections à entérovirus
- Infections à Picornaviridae
- Alcoolisme
- Hépatite
- Hépatite A
- Hépatite C
Autres numéros d'identification d'étude
- CRE 12-009
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Web-Based Brief Alcohol Intervention
-
Jimma UniversityArmauer Hansen Research Institute (AHRI)InconnueService de santé maternelleEthiopie
-
Heidelberg UniversityInconnueDélai de langue | Troubles développementaux du langageAllemagne
-
Hong Kong Baptist UniversityComplétéPhysiquement bien mais inquietHong Kong
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); The Hospital for Sick Children; St. Jude Children... et autres collaborateursComplété
-
Universidad de AlmeriaUniversitat Jaume IRecrutement
-
Taipei Medical UniversityRecrutementInfertilité | Variabilité de la fréquence cardiaque | BiofeedbackTaïwan
-
Northwestern UniversityComplétéMaladie rénale en phase terminaleÉtats-Unis
-
University of PittsburghComplétéConvivialité | Acceptabilité | Conformité des interventionsÉtats-Unis
-
Children's Hospital Medical Center, CincinnatiComplétéLivraison en ligne d'un traitement efficace pour la croissance de la fibrose kystique (Be In Charge)Fibrose kystiqueÉtats-Unis
-
Milton S. Hershey Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)ComplétéHypertensionÉtats-Unis